Starpharma expands accord with AstraZeneca

7 April 2014

Australian biotech firm Starpharma (ASX: SPL) has signed a second, expanded agreement with Anglo-Swedish drug major AstraZeneca (LSE: AZN) in the field of cancer medicine using Starpharma’s proprietary DEP dendrimer drug delivery technology.

The agreement follows on from an evaluation by AstraZeneca which began in September 2012 of Starpharma’s delivery technology. The new agreement will see the application of Starpharma’s technology to a cancer drug from AstraZeneca’s pipeline.

Under the new accord, AstraZeneca will provide funding for a preclinical stage cancer research program to be conducted jointly. Starpharma chief executive Jackie Fairley said the new deal does not yet involve milestone payments to Starpharma but allows the company's technology to be applied to a broader range of drugs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK